contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


lifecare-announces-second-clinical-trial-site-at-pfutzner-science-and-health-institute-in-mainz-germany

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Lifecare is a Norwegian company operating in medical technology. The company specializes in research and development of solutions for diabetes. The microsensors are injected under the skin of the patient's wrist, and also function as a real-time update of the patient's glucose level. In addition, the technology provides an alarm sensor and access to historical data on the patient's glucose level. The company was established in 2006 and is headquartered in Bergen, Norway.

Lifecare

Bergen, Norway, 30 May 2025 – Lifecare ASA (LIFE), a medtech company developing next-generation Continuous Glucose Monitoring (CGM) technology, is pleased to announce the selection of its second...

<div class="mfn-preamble"><p><strong>Bergen, Norway, 30 May 2025 – Lifecare ASA (LIFE), a medtech company developing next-generation Continuous Glucose Monitoring (CGM) technology, is pleased to announce the selection of its second clinical trial site: the Pfützner Science &amp; Health Institute (PSHI) in Mainz, Germany.</strong></p></div><div class="mfn-body"><p>This announcement follows Lifecare’s regulatory submission on 20 May 2025 for its first-in-human trial of the CGM implant, and the appointment of Professor Simon Nitter Dankel as Principal Investigator at the Research Unit for Health Surveys (RUHS), University of Bergen, as announced on 27 May 2025.</p><p>Lifecare’s planned clinical trial marks a key milestone on the path toward clinical validation and commercialization. Pending timely regulatory approval, Lifecare expects to finalize the trial by early Q4 2025, in line with budget and operational plans. The outcome will form the basis for initiating a pivotal CE-mark trial later this year, with finalization expected in 2026. A commercial launch of the CGM implant for human use is planned for 2027.</p><p>At PSHI, the trial will be conducted by&nbsp;Dr. Daniela Sachsenheimer<strong>&nbsp;</strong>and&nbsp;Dr. Julia Jantz<strong>,</strong> who will serve as site investigators. PSHI is a renowned institution specializing in metabolic research and clinical development. The institute is led by Lifecare’s Chief Scientific Officer,&nbsp;Prof. Dr. Dr. Andreas Pfützner, who also serves as owner and principal of PSHI.</p><p>Lifecare and PSHI share a long-standing collaboration. PSHI has previously conducted several key clinical and pre-clinical initiatives on behalf of Lifecare, including clinical trials in 2023.</p><p>"Expanding our clinical operations to PSHI in Germany brings valuable experience and continuity through the leadership of Drs. Sachsenheimer and Jantz," said&nbsp;Joacim Holter, CEO of Lifecare ASA. “Our long-standing partnership with PSHI provides a solid foundation for the successful execution of this trial.”</p><p>With RUHS in Norway and PSHI in Germany now confirmed as trial sites, Lifecare continues to advance its clinical roadmap for the wireless CGM implant, targeting completion of the initial trial in early Q4 2025 and transition into the pivotal CE-mark trial later this year.</p></div><div class="mfn-footer mfn-6f66f307be9c"><p><strong class="mfn-heading-1">About us</strong><br>Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring ("<strong>CGM</strong>") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.</p></div><div class="mfn-footer mfn-contacts mfn-742f7fc5e6f2"><p><strong class="mfn-heading-1">Contacts</strong><br>For further information, please contact:<br><br>Joacim Holter, CEO,  joacim.holter@lifecare.no, +47 40 05 90 40</p><p>Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42<br><br></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/fba8be9a-536f-4392-b801-d315e2ee730b/lifecare-announces-second-clinical-trial-site-at-pfutzner-science-and-health-institute-in-mainz-germany.pdf" class="mfn-generated mfn-primary">Lifecare announces second clinical trial site at Pfützner Science &amp; Health Institute in Mainz, Germany</a></p></div>

Lifecare announces second clinical trial site at Pfützner Science & Health Institute in Mainz, Germany